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The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop
resistance that might be overcome with drug combinations. However, the number of possible
combinations is vast, necessitating data-driven approaches to ﬁnd optimal patient-speciﬁc
treatments. Here we report AstraZeneca’s large drug combination dataset, consisting of
11,576 experiments from 910 combinations across 85 molecularly characterized cancer cell
lines, and results of a DREAM Challenge to evaluate computational strategies for predicting
synergistic drug pairs and biomarkers. 160 teams participated to provide a comprehensive
methodological development and benchmarking. Winning methods incorporate prior
knowledge of drug-target interactions. Synergy is predicted with an accuracy matching bio-
logical replicates for >60% of combinations. However, 20% of drug combinations are poorly
predicted by all methods. Genomic rationale for synergy predictions are identiﬁed, including
ADAM17 inhibitor antagonism when combined with PIK3CB/D inhibition contrasting to
synergy when combined with other PI3K-pathway inhibitors in PIK3CA mutant cells.
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P
ersonalized treatment matching targeted drugs to a tumor’s
genetics has resulted in remarkable responses. Unfortu-
nately, most patients’ tumors develop resistance leading to
disease relapse. There are multiple mechanisms that may lead
to drug resistance1 that include genetic and non-genetic hetero-
geneity inherent in advanced cancers, coupled with complex
feedback and regulatory mechanisms, and dynamic interactions
between tumor cells and their microenvironment. Any single
therapy may be limited in its effectiveness, but drug combinations
are hypothesized to potentially overcome drug resistance and lead
to more durable responses in patients. The molecular makeup of
cancer cells and the mechanisms driving resistance will inﬂuence
the optimal combination of mechanisms to target1–3.
High-throughput preclinical approaches are crucial to deter-
mine and evaluate effective combination strategies. While
empirical experiments are important for observing potential
synergistic properties across drug pairs, the possible number of
combinations grows exponentially with the number of drugs
under consideration. This is further complicated by the inﬂuence
of disease and cellular contexts, rendering it impractical to cover
all possibilities with undirected experimental screens4. Compu-
tational approaches for predicting drug synergy are critical to
guide experimental approaches for discovery of rational combi-
nation therapy5.
A number of approaches have been developed to model drug
combination synergy using chemical, biological, and molecular
data from cancer cell lines6,7 but with limited translatability to the
clinic. A key bottleneck in the development of such models has
been a lack of public data of sufﬁcient size and variety to train
computational approaches4,8, particularly considering the diver-
sity of biological mechanisms that may inﬂuence drug response.
A further limit to the translatability of many computational
approaches is their reliance on data features that may not be
present during the course of patient care, such as on-treatment
tumor molecular proﬁles.
To accelerate the understanding of drug combination synergy,
Dialog for Reverse Engineering Assessments and Methods
(DREAM) Challenges partnered with AstraZeneca and the Sanger
Institute to launch the AstraZeneca-Sanger Drug Combination
Prediction DREAM Challenge. DREAM Challenges (dreamchal-
lenges.org[www.dreamchallenges.org]) are collaborative compe-
titions that pose important biomedical questions to the scientiﬁc
community, and evaluate participants’ predictions in a statisti-
cally rigorous and unbiased way, emphasizing model reproduci-
bility, and methodological transparency9.
This Challenge was designed to explore fundamental traits that
underlie effective combination treatments and synergistic drug
behavior. Speciﬁcally, it was structured to address the following
translational questions using data available prior to drug treat-
ment (mirroring a clinically relevant scenario to direct ther-
apeutic choice): [i] how to predict whether a known (previously
tested) drug combination will be effective for a speciﬁc patient;
[ii] how to predict which new (untested) drug combinations are
likely to yield synergistic behaviors in a patient population; and
[iii] how to identify novel biomarkers that may help reveal
underlying mechanisms related to drug synergy.
We shared with the scientiﬁc community 11,576 experimen-
tally tested drug combinations on 85 cancer cell lines. Molecular
data was provided for the untreated (baseline) cell lines, alongside
chemical information for the respective drugs. Participants used
the described data to train and test models, and were encouraged
to extend computational techniques to leverage a priori knowl-
edge of cellular signaling networks.
In this manuscript, we report on the results of this Challenge
where we have identiﬁed novel and performant methods using a
rigorous evaluation framework on previously unpublished data.
We describe the details of these approaches, as well as general
trends arising from the meta-analysis of all submissions. The full
dataset, along with methods and scoring functions, are freely
provided to the research community, and available to benchmark
future algorithms in the ﬁeld. Finally, we describe putative
mechanistic models derived from the observed predictive features
underlying synergistic responses, particularly between receptor
tyrosine kinase and PI3K/AKT pathway inhibitors.
Results
A large high-throughput drug combination screen. We collated
a combinatorial drug sensitivity screen comprising 11,576
experiments each measured in a 6-by-6 dose matrix (Methods)
across 85 cancer cell lines. A synergy and an antagonism dis-
tribution (Loewe reference model10,11) were calculated and
summarized via a single score for each experimental matrix
(Methods; Supplementary Fig. 1 and Supplementary Data 1). The
resulting dataset included highly reproducible cell viability
response measurements and synergy scores for 910 pairwise
combinations of 118 drugs (Supplementary Fig. 2 and Methods),
plus information on the drugs including putative drug targets and
their chemical properties. We also integrated deep molecular
characterization of these same cell lines, including somatic
mutations, copy-number alterations, DNA methylation, and gene
expression proﬁles (Fig. 1a–c) measured before drug treatment12.
The 85 cell lines were predominantly derived from tumors of
the breast (N= 34), lung (N= 22), bladder (N= 14), and the
gastrointestinal tract (N= 12) (Fig. 1d). Drug synergy score
distributions varied across disease types (Fig. 1d); in particular
lung cell lines had over twofold higher mean synergy than breast
cell lines (t-test P= 7e-27). Of the 118 drugs tested, 59 were
targeted therapies against components of oncogenic signaling
pathways (Methods), 15 of which target receptor tyrosine kinases
(RTKs), 22 target PI3K/AKT signaling, and 9 target MAPK
signaling (Fig. 1e, f). Across the pairwise drug combination
experiments, 88% (N= 797) of the unique pairs had drug targets
within the same signaling pathway and demonstrated markedly
overall higher synergy scores (average of 17.3 vs. 7.3, t-test P=
2e–18) than the remaining 12% (N= 113) whose drug targets
were deﬁned to be in distinct pathways. As part of the Challenge
design, we ensured that drug targeted pathways and cancer types
were proportionally distributed across sub-challenges and train-
ing/test datasets (Fig. 1g). Sparsity in the cell line drug
combination data matrix (Fig. 1g) resulted as several drug
combinations were selectively proﬁled in clinically relevant cancer
cell lines, e.g., ESR1 inhibitors were predominantly combined
with other drugs in estrogen receptor-positive breast cancer cell
lines since these agents are standard of care within this cancer
subtype.
Comparison of AZ-DREAM to published combination screens.
We compared the AstraZeneca-DREAM (AZ-DREAM) challenge
dataset with the independently published in vitro combination
screening studies by O’Neil et al.4 and ALMANAC13. All three
studies used different experimental designs and protocols (Fig. 2a
and Supplementary Table 1), with AZ-DREAM exploring screens
with a 5-by-5 concentration titration format, O’Neill et al.4 a 4-
by-4 format, and ALMANAC a 3-by-3 format. The overlap is
limited in cell lines, targets and drugs explored: 10 cells and 7
targets, 4 drugs and 0 combination-cell pairs shared between AZ-
DREAM and O’Neil et al.4; and 15 cells, 28 targets, 19 drugs, and
10 combination-cell pairs shared between AZ-DREAM and
ALMANAC. AZ-DREAM provides greater coverage of targeted
agents and greater numbers of cell lines per tumor type (Sup-
plementary Table 1).
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For the AZ-DREAM and ALMANAC comparison, only nine
experiments passing quality control (Supplementary Methods)
had the same combination tested in the same cell line, comprising
geﬁtinib combined with either tamoxifen, fulvestrant, vorinostat,
crizotinib, or everolimus, and tested in two breast cancer cell lines
(MCF7 or T47D). Encouragingly, all but one experiment were
concordantly identiﬁed synergistic with the same effect signs seen
in AZ-DREAM and ALMANAC (Fig. 2b). Within the nine
overlapping experiments, 38 titrations were identically used by
both ALMANAC and AZ-DREAM (Supplementary Fig. 3 and
Supplementary Fig. 4a). For these 38 titrations we observed a
correlation >0.7 (Fig. 2c and P < 10−7, test for association)
between cell viability measures from AZ-DREAM and ALMA-
NAC, maintained for individual combinations and cell lines
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where the number of data points was sufﬁcient (Supplementary
Fig. 4).
While there were ten cell lines and four drugs found in both
AZ-DREAM and O’Neil et al.4, no combination-cell experiment
was shared between those two screens. O’Neill et al.4 data
displayed lower dispersion of synergy scores (Supplementary
Fig. 2c, d) and fewer instances of extreme synergy scores. The
technical reproducibility within these screens, however, was
comparable, with a similar correlation observed between
replicated experiments (Spearman= 0.63 for O'Neil et al.,4
Spearman= 0.56 for AZ-DREAM).
We derived a RECIST-like response measure from the AZ-
DREAM in vitro data (see Methods) to enable comparison to
in vivo response metrics for the eight overlapping combinations
in patient-derived tumor xenograft (PDX) models published by
Gao et al.8 (Supplementary Data 1 and Supplementary Fig. 5a).
We compared the % PDX models with synergy in Gao et al.4,8 to
the % cell lines with synergy in AZ-DREAM. A concordant trend
was observed (Pearson r= 0.34, P= 0.42; Methods; Supplemen-
tary Fig. 5b), although too few combinations were shared between
the datasets to conclude with statistical conﬁdence.
Benchmarking of methods reveal high prediction accuracy. The
Challenge was divided into two primary sub-challenges. In sub-
challenge 1 (SC1) participants were asked to predict continuous
synergy scores for drug combinations for which training data
on those same combinations were available. In sub-challenge 2
(SC2), participants were asked to predict binary synergy status
on drug combinations for which no training data was provided,
thereby requiring participants to infer synergy using transferable
data/knowledge patterns identiﬁed from previously seen
independent drug pairs. SC1 was further subdivided into two
parts: SC1A allowed the use of all available data for model pre-
diction, while SC1B limited data use to just mutation and copy-
number variation (mimicking current clinical assay feasibility).
A total of 969 participants of diverse geography and expertize
registered for the Challenge (Supplementary Fig. 6a, b). One-
hundred sixty teams submitted across any portion of the
Challenge and 78 teams submitted for ﬁnal assessment.
Speciﬁcally, SC1A received ﬁnal submissions from 76 teams, 62
for SC1B and 39 for SC2.
As scoring metric we used the average weighted Pearson
correlation between the continuous endpoints of predicted and
known synergy values for SC1, and both the –log10(p) from a 3-
way analysis of variance (ANOVA) and balanced accuracy (BAC)
for SC2 where predictions were binary (Methods). Across all
teams, mean performance scores were r= 0.24 ± 0.01 and r=
0.23 ± 0.01 (weighted Pearson correlation ± standard error) for
SC1A and SC1B, respectively, and –log10(p)= 12.6 (3-way
ANOVA) for SC2. Despite omitting several input data types,
teams performed only slightly worse for SC1B, Δprimary metric
= 0.01 (t-test P= 0.90), compared to SC1A (Fig. 3a and
Supplementary Fig. 6c, d). While teams employed many different
methodological approaches to modeling drug synergy—including
regression, decision trees, random forests, Gaussian processes,
SVM, neural networks, text mining, mechanistic network-based,
and others (Supplementary Fig. 7a)—algorithm class showed little
relationship to performance (Supplementary Fig. 7b). The top
winning team in all three sub-challenge was Yuanfang Guan
(Y Guan) with primary metrics of 0.48, 0.45, and 74.89 in SC1A,
SC1B, and SC2, respectively. Based on the primary metric in SC2,
Y Guan performed considerably better (Methods; >5 Bayes
Factor, based on bootstrapped metrics’ comparisons) than other
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teams (Fig. 3b). All performance statistics and team rankings are
available at the Challenge website (synapse.org/DrugCombina-
tionChallenge[https://www.synapse.org/#!Synapse:syn4231880/
wiki/235649]).
To benchmark the performance of teams in the ﬁnal rounds of
SC1A/B and SC2, we established lower and upper bounds of
performance. We deﬁned the lower bound as the null model, i.e.,
random permutation of the synergy data across each cell line (see
‘Code availability’’ section). We would not expect algorithms to
predict better than the reproducibility observed between replicate
experiments. We therefore identiﬁed cases for which replicate
measurements (same drug/combination tested independently in
the same cell line) were available and assessed the primary metric
achieved when using one measure to predict the other. We
set this metric value as our upper-bound. We observed that
83%, 85%, and 94% of submitted models performed better
than random (Methods; 5% false discovery rate, FDR) for
SC1A, SC1B, and SC2, respectively. Team performances varied
widely, but remarkably the top 15 models (20%) submitted to
SC1A all reached a performance level comparable to experimental
replicates (primary metric= 0.43; Fig. 3a), as did the top 13
models (21%) in SC1B. Proportionally fewer teams performed at
the level of replicate experiments in SC2 based on the BAC, with
North Atlantic Dream (NAD) achieving the best performance
(BAC= 0.688; Fig. 3c).
Given the less robust performance of SC2, we assessed whether
an ensemble method—based on an aggregation of all submitted
models—could yield a better overall model, a phenomenon called
“wisdom of the crowd”9,14. By applying a Spectral Meta-Learner
(SML)15 as our ensembl approach, we achieved a modest
improvement in performance (BAC= 0.693) over the best
performing individual team (BAC= 0.688), as well as an
ensemble of randomly selected models (BAC= 0.63, (Fig. 3d).
Leveraging biological relationships improves predictions. A
common strategy among top-performing teams (DMIS, NAD,
and Y Guan) was to ﬁlter molecular features, leaving only those
related to known cancer drivers for subsequent modeling (Sup-
plementary Methods). These teams also consolidated pharma-
cological and/or functional pathway information associated with
the molecular drug target, enabling one drug’s model to learn
from data generated for another drug with the same target
(Y Guan16 and NAD16–18).
We took two approaches to analyze each feature type’s
importance, particularly whether incorporating molecular fea-
tures and chemical/biological knowledge can increase prediction
accuracy. In the ﬁrst approach, we generated a baseline model
(following Team NAD’s method) utilizing only cell line and drug
labels as input features as per SC1B. We then assessed changes in
the primary metric after the substitution or addition of feature
types (Fig. 4a and Supplementary Methods). In the second
approach, we started with the DMIS model obtained from SC1B,
and then iteratively removed single feature types and pairs of
features to assess changes in prediction accuracy (Fig. 4b and
Supplementary Methods).
Surprisingly, high primary metrics were observed for the NAD
baseline model where the only input features were drug and cell
line label (Fig. 4a, 0.32). Drug target was the only feature to
improve performance of the NAD baseline model when swapped
with drug label (Fig. 4a, t-test P= 0.012). Furthermore, removing
both drug label and target resulted in the highest performance
drop for the DMIS model (Fig. 4b, −0.17). This result highlights
the importance of the global cell-line state in predicting drug
synergy, and how drug target information shared across drugs
can facilitate transfer learning across separate models. Mutational
and copy-number variation (CNV) data can similarly offer a
barcode of cell identity to encode cell line label. However,
where mutation data improved performance when replacing cell
line labels, replacement with CNV decreased performance
signiﬁcantly (Fig. 4a, t-test P= 8.8e-6). Importantly, in all cases
additional feature data increased performance when added to the
NAD baseline model (Fig. 4a, t-test P= 0.009, 0.009, 0.002, 0.008,
0.021 adding drug target, KEGG pathway, Gene Ontology,
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feature types are removed at once (off diagonal)
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signaling network, and mutation features, respectively). Ensemble
of different feature sets improved prediction most when
collectively increasing coverage of biological (pathway) complex-
ity (Fig. 4a, t-test P= 1.2e-6).
Inspecting consistently poorly predicted drug combinations.
While a global performance metric applied to all cell-lines and
drug combinations provides a broad assessment of model pre-
diction accuracy, we hypothesized that some models may be
optimized for certain subclasses of combinations and/or tumor
types. We assessed the Pearson correlation between predicted and
observed synergy scores for each combination in SC1A/B, and
clustered teams by correlation of performance across combina-
tions. Of the 118 combinations that had observed synergy scores
>20 in more than one cell line, we identiﬁed 22 combinations
predicted poorly by all participants (Fig. 5a, Methods), and over
50 combinations predicted well across all teams.
Combinations tested across a higher diversity of tumor types
tended to show lower overall performance (Supplementary
Fig. 8a; t-test P= 0.04), indicating that a pan-cancer prediction
presents a more difﬁcult prediction task. Combinations tested
across more tumor types were also tested across greater numbers
of experiments (Supplementary Fig. 8b; Spearman= 0.56,
P= 2.3e–15), but no signiﬁcant difference was observed between
performance and number of experiments within a cancer type
speciﬁc setting (Supplementary Fig. 8c, d). On average the quality
assessment scores were signiﬁcantly better (t-test P= 0.018) for
the pharmacology experiments in the training set of well
predicted compared to poorly predicted combinations (Supple-
mentary Fig. 8e). Comparable trends were seen between the
quality of synergy and predictive performance in the training
and test sets (Supplementary Fig. 8f; r= 0.52 vs. 0.43). The
distribution of synergy scores were similar between poorly and
well predicted combinations (Supplementary Fig. 8g) as were
the proportion of synergistic cases (37% for poorly predicted vs.
39% for well predicted).
Well predicted cases were enriched for combinations inhibiting
both the PI3K/AKT and MAPK pathways (Fig. 5b, average
Pearson r= 0.37 vs. 0.25; t-test P= 0.008), or apoptosis pathway
combined with either metabolism, cell cycle, or receptor tyrosine
kinase pathways. The drugs targeting these pathways were
prevalent in our dataset, but these speciﬁc combinations of those
drugs were not (Supplementary Fig. 9a). Assessment of the
interactions between drug targets and neighboring proteins from
OmniPath, a comprehensive compendium of literature-based
pathway resources19, revealed no differences in the somatic
alteration frequency for targets or their ﬁrst neighbors between
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the poorly and well predicted combinations (Supplementary
Fig. 9b, c). We did observe a signiﬁcant enrichment of well
predicted combinations where both drugs’ respective targets were
downstream of a common neighboring protein (Fig. 5c, t-test
P= 0.01), and conversely, we observed an enrichment of poorly
predicted combinations where targets were both up-stream
(Fig. 5c, t-test P= 0.03). There was no signiﬁcant difference
(Chi-sqr P= 0.44) in OmniPath protein network distance
between drug targets for well and poorly predicted combinations
(Fig. 5d), nor any correlation between either network distance
and average/median synergy scores (Fig. 5e) or the number of
cases with synergy >20. Combinations where targets were found
to not be connected in a protein network had signiﬁcantly
lower average synergy (t-test P= 0.031) and lower max synergy
(t-test P= 0.0021).
Biomarkers of drug combination synergies. A limitation of
many machine learning algorithms is the lack of feature inter-
pretability and experimentally testable logic-based rules. We took
two approaches to identify biomarkers that may be predictive of
drug synergies: a direct survey of participants through which
predictive features were nominated for each drug pair (Supple-
mentary Data 2); and retrospective work focusing on results from
two of the best performing teams, NAD and DMIS, to decon-
volute features most impactful to model predictions (Supple-
mentary Fig. 10 and Supplementary Data 3).
The survey-submitted biomarker results varied in detail and
depth (Supplementary Data 2), but common genetic markers
were apparent across good predictions in SC1B, including EGFR,
ERBB2, PIK3CA, PTEN, TP53, or RB1. In the survey, synergy was
commonly assigned to drug pairs targeting directly down- or up-
stream of a mutated, ampliﬁed, overexpressed or deleted cancer
gene. We hypothesized that drug synergy may result when one
drug overcomes a resistance mechanism for the other. Focusing
on mutations in cancer genes (as deﬁned by Iorio et al.12) we
identiﬁed all mutations associated with resistance to monother-
apy in our data (Supplementary Methods and Methods) selected
at increasingly stringent P-value (wilcoxon rank sum test)
thresholds (Supplementary Methods and Methods). For each
threshold, we then assessed the likelihood of synergy seen from
combinations paired to these monotherapies in the presence vs.
absence of the respective mutation. We observed an increase in
the proportion of synergistic drug combinations with each
increase in threshold stringency (Fig. 6a, Pearson r=−0.90, P
= 4.09e-38). We observed the same trend in patient-derived
xenograft (PDX) models (Fig. 6b, Pearson r=−0.95, P= 2.2e-
49). This observation supports the notion that drug sensitivity
may be restored with drug combinations targeting a resistance
driver.
We also explored models of best performing teams and their
chosen features, focusing on biomarker associations aligned to
combinations for which the respective team had achieved a robust
prediction accuracy (Pearson r > 0.5), with particular interest in
the genetic biomarkers revealed through SC1B. Multiple criteria
for quality, independence and reproducibility (Methods)4,8 were
applied yielding 13 feature-to-combination associations (Fig. 7a
and Supplementary Data 3), seven associated with synergy and
six with non-synergy. To assess whether these associations could
be independently validated as synergistic biomarkers, we explored
nine overlapping and 21 non-overlapping (independent) cell
lines in O’Neil et al.4 (Fig. 7b) that were treated with similar drug
combinations, i.e., same putative drug targets. Concordance of
association was observed in the nine overlapping cell lines (Fig. 7c;
six out of seven associations, ~86%) and in the 21 independent cell
lines (Fig. 7d; eight out of eleven associations, ~72%).
Among the prioritized feature-to-combination associations
were several genetic variants associated with synergistic responses
to the combination of receptor tyrosine kinase (RTK) inhibitors
with inhibitors of the downstream PI3K/AKT pathway. Ampli-
ﬁcations or activating mutations in EGFR or ERBB2 consistently
predicted synergy from inhibition of the RTK+ PI3K/AKT
pathways across multiple independent drugs and datasets
(Fig. 7a). Less direct relationships were also observed, including
combined AKT inhibition with either IGFR inhibition in the
ERBB2 mutant setting or FGFR inhibition in the EGFR mutant
setting (Supplementary Data 3). Despite kinase domain homology
it is unlikely these observations are explained by off-target effects
since EGFR, ERBB2, and FGFR mutations were only predictive of
respective monotherapy responses (Supplementary Fig. 11).
Combinations inhibiting multiple points within the PI3K/AKT
pathway also showed synergy in the presence of up-stream
activation from mutations in PIK3CA or deleterious events in
PTEN (Fig. 7a, e). Inhibition of the metalloproteinase ADAM17,
known to inﬂuence RTK activity20, also showed synergistic
responses in a common subset of cell lines when combined with
inhibitors of PIK3C-pan or AKT1/2 (Fig. 7a and Supplementary
Data 3), with a notable exception of PIK3CB/D selective
inhibitors, which show antagonism unique to PIK3CA mutant
cell lines (Fig. 7e, f). Ampliﬁcation and activating mutations in
Androgen Receptor (AR) were also found to be associated with
antagonistic effects when targeting AKT in combination with
MAP2K or IGFR inhibitors (Fig. 7a).
Translatability of synergy and biomarker predictions. We
assessed the performance of top-performing AstraZeneca-
DREAM models on the independent screening datasets by O’Neil
et al.4 and ALMANAC13. Since no combination-cell experiments
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directly overlapped AZ-DREAM and O’Neil et al.4, we collapsed
drugs by shared targets to expand the overlap. We observed that
SC1A models from NAD and DMIS outperformed random
models (Fig. 8a, mean primary metric= 0.07, top 1% of random
models) for cell lines and drug target combinations non-
overlapping between O’Neill et al. and AZ-DREAM data (Sup-
plementary Data 1). Interestingly, no substantial performance
increase was observed when independent model predictions were
made for the ten cell lines in common between the two datasets,
nor the 30 combinations with similar chemical/target properties
(Supplementary Table 2 and Fig. 8b–d). As in the main Chal-
lenge, combining these two or more models in an ensemble led to
an improved prediction performance (Fig. 8a–d).
Considering the limited overlap and correlation of synergies
between AZ-DREAM and ALMANAC datasets, high perfor-
mance was not expected when predicting ALMANAC synergy
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scores with models trained on AZ-DREAM data points alone, as
was observed for the NAD model. We trained two NAD models
on 50% of the ALMANAC data: ﬁrst a baseline model to show
maximum performance achievable when using only cell and
drug label features as input; and a second allowing use of the full
feature set as input. The full model consistently predicted
signiﬁcantly better than baseline in the remaining 50% over ten
randomized iterations, giving conﬁdence in the transferability of
the method designed for AZ-DREAM. Best performance was
observed for targeted combinations (r= 0.369 vs. 0.287 for full
NAD and baseline NAD model, ANOVA P= 1.322e-31 for
model type and P= 5.5e-05 for model type and targeted therapy
association, Fig. 8e).
Exploring AZ-DREAM biomarker associations prioritized as
described in earlier sections, we assessed statistical association
for drug combinations with consistent targets in the O’Neil et al.4
dataset. In the ten cell lines overlapping the AZ-DREAM and
O’Neil et al.4 datasets, seven of the prioritized biomarker-
drug combinations were present, of which six (86%) showed
reproducible directionality (FDR < 35%, Fig. 7c). In the 21 O’Neil
et al.4 cell lines not used within AZ-DREAM training, 11 of the
prioritized biomarker-drug combinations were present, of which
8 (72%) showed reproducible directionality (Fig. 7d).
Discussion
The objective of this AstraZeneca-DREAM Challenge was to
drive the development of innovative computational approaches
to predict novel drug combinations and to comprehensively
benchmark these approaches. To enable this we made one of the
largest in vitro drug combinatorial screens to date available to
the scientiﬁc community. We cover largely non-overlapping
experiments to existing datasets and, in particular, offer extensive
data for targeted therapies complimenting the non-targeted
chemotherapeutic agents covered in the NCI-ALMANAC.
Despite little overlap we demonstrated an encouraging reprodu-
cibility of data and predictions between screens, particularly
when considering the confounding differences in experimental
designs and assay formats21. Furthermore, we showed that some
trends represented in these data can be reproduced in vivo, and
that clinically efﬁcacious combination pairs can be identiﬁed.
Our double-blinded benchmark of 78 methods provides an
unbiased comprehensive evaluation of the state-of-art of drug
synergy prediction. Collectively this Challenge manuscript equips
the scientiﬁc community with data and a methodological baseline
for algorithm development, alongside a suite of computational
methods to direct new experiments towards likely synergistic
drug combinations.
The results of the AstraZeneca-Sanger Drug Combination
Prediction DREAM Challenge have shed important light on the
best practices and limitations in predicting drug synergy. By
evaluating predictions from a large number of teams, we were
able to discern important strategies for predicting drug synergy
from molecular and chemical traits. As with most DREAM
Challenges, we observed that the machine learning method itself
has little impact on overall performance. Aggressive pre-ﬁltering
that incorporates clean sparse network data to consider feature
relevance to drug targets and cancer was successfully used by top
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performers to limit model complexity and improve model gen-
eralizability. Despite the complexity of the problem, many teams
reached the upper-bound of performance levels based on varia-
bility in experimental replicates. This was further conﬁrmed when
top-performing models were applied to an independent dataset,
demonstrating robustness to assay variability, and context
heterogeneity.
A comprehensive assessment of the predictive value of
monotherapy was not completed in the Challenge format, in part
due to initial miss-annotation of data. However, post-hoc ana-
lyses suggested it offered no signiﬁcant improvement to well-
performing models (Supplementary Fig. 12). Despite minimal
predictivity from monotherapy itself as a feature, biomarkers
associated with monotherapy resistance were observed to have
predictive value for respective combinations. Looking forward,
additional attention is also required for the one-ﬁfth of combi-
nations poorly predicted by all Challenge teams. The rationale
differentiating these combinations is non-obvious but our data
suggests, in part, some relationship to the complexity of network
connectivity between drug targets and proximal biomarkers
(Fig. 5c), perhaps a bias introduced by network-led dimension
reduction techniques employed by well-performing models.
Furthermore higher synergy scores were observed—in some
combinations—when both drugs target downstream of a com-
monly interacting protein22. Collectively, these observations
advocate for a more biologically rationalized approach to bio-
marker discovery, accounting for directionality and exclusivity
of signaling and functional relationships between biomarkers
and targets.
A notable absence from the Challenge was the use of mathe-
matical, reaction- or logic-based mechanistic pathway modeling
approaches23–27, likely due to the higher time and data input
needed for model creation. The dynamic nature of mechanistic
models may offer an advantage by enabling consideration of the
heterogeneity that exists across even apparently ‘clonal’’ cell line
populations28. The increasing availability of published pre-
derived mechanistic models for many cancer relevant pathways
may soon make such an approach more viable. Given the strong
beneﬁt seen from inclusion of prior-knowledge, and as text-based
artiﬁcial intelligence technology matures, computational approa-
ches, such as natural language processing (NLP) to harness
knowledge from world literature may also become of signiﬁcant
beneﬁt. Alternatively, more generic signatures of dynamic (e.g.,
transcriptional) output may ﬁrst be used to identify a mechanistic
rationale28–31 to which causative genetic or epigenetic events
can then be inferred and aligned as predictive features32,33. A
surprising result of our Challenge, however, suggested only
modest improvement to prediction from inclusion of all data in
SC1A compared to only genetics in SC1B.
To maximize potential for translation it is essential that
modeling approaches reveal testable biological insight, parti-
cularly considering that this and prior Challenges show no
predictive advantage to black box algorithms. As we discovered,
however, it can be difﬁcult to incentivize knowledge retrieval
within a competition format that focuses on objective scoring of
performance. Despite these limitations, we were able to
extract important insights to biomarkers for certain drug
combinations. Given the dominance of RTK and PI3K/AKT
pathway targeting agents in the Challenge data, it was not
surprising that these revealed some of our strongest
combination-feature relationships. In multiple cases this
aligned to a two-hit hypothesis targeting the activating driver
with a downstream pathway component. These included
synergies between EGFR and AKT inhibitors in the presence
of activating EGFR mutations34, or AKT1/2 with pan-PI3K
inhibitors in the presence of pathway activating mutations
in PIK3CA or PTEN. In some cases the biomarker rationale
for AKT inhibitor synergy with RTK or MAPK inhibition was
less direct but indicative of crosstalk and feedback signaling
previously reported35. Interestingly antagonism was observed
in cell lines harboring activating mutations of AR36–39. Feed-
back signaling resulting from AKT inhibition has been seen
to drive AR activity, which in turn can lead to the activation
of the MAPK cascade39,40, attenuating respectively targeting
drug activity.
The synergy observed between ADAM17 and PI3K/AKT
pathway inhibitors may work through independent inhibition of
multiple cancer hallmarks, or via a more direct mechanism
whereby inhibition of ADAM17 driven proteolysis and shedding
of RTKs20 stabilizes and increases signaling through PI3K/
AKT41,42. Notably ADAM17 predominantly inﬂuences RTK’s
other than EGFR/ERBB220, and no beneﬁt is seen in cells with
mutations in these genes. ADAM17 inhibition, however, showed
antagonism unique to combined PIK3CB/D selective inhibitors
within the PIK3CA mutant setting. Reduced synergy may result
from a lessened dependency on PI3K paralogues in the presence
of constitutively activated PIK3CA, or reduced beneﬁt from
ADAM17 loss in the extreme luminal/epithelial physiology of
PIK3CA mutants. The apparent antagonism, however, suggests
feedback following PIK3CB/D inhibition enhances mutant
PIK3CA expression/activity. Indeed PIK3CB inhibition has been
shown to result in elevated expression and activity of PIK3CA43,
and may also relieve the inhibitory effects of substrate competi-
tion or dimerization between PIK3CA and PIK3CB/D.
Many drug combinations effective in the clinic to date involve
mechanistically distinct agents, often chemotherapies combined
with an additional targeted therapy, for which beneﬁt may arise
from the independent effects of the drugs on different sub-
populations44 rather than synergy. More recently, an increasing
number of combinations include multiple targeted therapies5.
Hence, identifying both molecularly synergistic and com-
plementary drugs, and how these affect inter- and intra-patient
heterogeneity remains an essential area of future research. Future
Challenges should further address the question of how to opti-
mize translation of preclinical results into the clinic45. Where this
Challenge addressed prediction of synergy for combinations of
known drugs, an ability to predict truly novel beneﬁcial target
combinations should also be explored. Furthermore, the space of
therapeutic combinations should be extended to include >2 drugs,
and covering targets in independent cell types, such as subclonal
tumor cell populations or cells of the tumor microenvironment
and immune system3. These approaches can be complemented
by adaptive and sequential strategies reactive to monitoring of
the patient tumor and physiology. Success in these areas will
be dependent on the availability and access to large-scale data
needed for model development and validation. Public-private
partnerships—as exempliﬁed by this Challenge and AstraZeneca’s
generous sharing of data with the research community—will be
critical to future efforts.
Methods
Drug combination screening. All cell lines were authenticated at AstraZeneca cell
banking using DNA ﬁngerprinting short-tandem repeat assays and each bank is
conﬁrmed to be free from mycoplasma. Cells ordered from the global cell bank are
cultured for up to 20 passages. Cell suspensions are counted using a haemocyt-
ometer and cells are re-suspended in full growth medium containing Pen/Strep to
a ﬁnal density for different cell line densities and for different seeding densities into
384-well cell culture plate. A volume of cells as determined by cell count and
dependent on cell type was added to each well of a Greiner 384-well plate using
a Multidrop Combi liquid handler and then incubated at 37 °C and 5% CO2
overnight in a rotating incubator. After seeding, plates were shaken to distribute
the cells more evenly at the bottom of the wells and left to stand on the bench for
1 h to allow even settling of cells.
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Drug combinations were screened with four combinations per 384-well plate in
a 6-by-6 range of concentration format. The ﬁrst row and ﬁrst column in the 6-by-
6 matrix are monotherapies of each drug in the combination, while the top left
corner is the untreated control. Drug combinations therefore were tested in a 5-by-
5 layout with comprehensively rescreening the monotherapy and control for each
experiment to minimize batch effects. Drug concentrations ran from the highest
dose to the lowest dose. All plates were dosed with drugs solubilized in DMSO
or PBS, or DMSO alone to provide comparable treatment and max control wells.
After 5 days of incubation 5 µl of 2 µM Sytox Green working solution was added
to each well of the 384-well plates (0.133 µM ﬁnal concentration) and the plates
incubated for 1 h at room temperature. After incubation plates were read by the
Acumen laser scanner to detect the number of Sytox Green stained cells. The total
ﬂuorescent intensity across the well was then read and the number of dead cells
calculated by dividing this total ﬂuorescence by the ﬂuorescence of a single cell. The
plates were re-read on the Acumen to give a total cell count. A live cell count was
then determined by subtracting the dead cell count from the total cell count.
Quantifying combination synergy and antagonism. Synergy and antagonism
were quantiﬁed in an automated way using freely available Combeneﬁt software
(v1.31)11. The approach implemented in Combeneﬁt is based on quantifying
synergy distribution by comparing a drugs combination experimental dose-
response surface to a modeled reference based on individual drugs dose-response
curves. Brieﬂy, for each 6-by-6 matrix, monotherapy dose-responses were extracted
and modeled as a sigmoidal curve via the Hill equation46. A reference dose-
response surface is then generated by Combeneﬁt based on the Loewe model of
additive combinations and the single drug dose-response curves. The experimental
combination dose–response surface is then compared by the software to the model-
generated one, resulting in a synergy distribution in concentration space. This
synergy distribution is ﬁnally further summarized by integrating the synergy
distribution in logarithmic concentration space. The procedure resulted in a single
score (the result of this integration) for each combination.
In vivo response class deﬁnitions. Response data for 62 treatments across ~1000
PDX models were derived from Gao et al.8 Putative drug targets from the AZ-
DREAM and Gao et al.4,8 dataset were utilized to identify overlap. As synergy
scores were not available for the Gao et al.4,8 dataset, ‘Best Response’’ (complete
response-CR, partial response-PR, stable disease-SD, progressive disease-PD) for
each combination-PDX pair were extracted and compared with monotherapy ‘Best
Response’’ of each drug in the combination on the same PDX model. This was
represented numerically where CR= 4, PR= 3, SD= 2, and PD= 1. Synergy was
assigned to a change of +2 or more, and Antagonism to a change of −2 or less. A
change of +1, 0, or −1 was assigned Additive, considering an element of experi-
mental variability. Cases where best response has been observed as a range over
time (PR→→PD), the earliest response was considered as we hypothesize this to
reﬂect in vitro response in a more realistic sense for comparison.
The percent tumor volume change class deﬁnitions are as following:
1. Synergistic efﬁcacy: Combination treatment leads to better tumor regression
than either monotherapy.
2. Synergistic non-efﬁcacy: Combination response is better than either
monotherapy but does not result in tumor regression.
3. Additivity: Combination response same as the better of either monotherapy
responses.
4. Non-synergistic efﬁcacy: Combination response weaker than the better of the
monotherapy responses but results in tumor regression.
5. Antagonism: Combination response weaker than both monotherapies.
In vitro response class deﬁnitions. Response scores deﬁned by the Loewe synergy
model were considered in ordered to deﬁne in vitro response classes. Synergism
was deﬁned as Loewe scores ≥20, Antagonism ≤−20, and rest are classed as
Additive.
Molecular characterization. The 85 cell lines were molecularly characterized,
including:
1. Mutations from whole exome sequencing with Illumina HiSeq 2000 Agilent
SureSelect (EGAS00001000978)
2. Copy-number variants from Affymetrix SNP6.0 microarrays
(EGAS00001000978)
3. Gene expression from Affymetrix Human Genome U219 array plates (E-
MTAB-3610)
4. DNA methylation from Inﬁnium HumanMethylation450 v1.2 BeadChip
(GSE68379)
Mutations were called with CAVEMAN [https://github.com/cancerit/
CaVEMan/]47 and PINDEL [http://gmt.genome.wustl.edu/packages/pindel/]48 as
reported in ref. 12. Variants were provided without further ﬁltering, including
putative passenger mutations, germline variants, and potential cell line artefacts,
which are in total 75,281 mutations in 85 cell lines.
Copy-number variants (CNVs) are called with the PICNIC [http://www.sanger.
ac.uk/resources/software/picnic/]49 algorithm using the human genome build 38
as the reference. CNVs might be wild type, deletion, or ampliﬁcation of certain
segments in a chromosome. One or multiple genes can fall within such segments.
We reported copy number for the major and minor allele on gene and
segment level.
Gene expression was processed as described in ref. 12, including Robust Multi-
array Average (RMA) normalization with the R-package ‘affy’’50. Gene expression
for 83 cell lines across 17,419 genes (HGNC labels) was reported; no expression
was available for MDA-MB-175-VII and NCI-H1437.
DNA methylation was reported for 82 cell lines the beta and M values51 for
287,450 probes; no methylation was available for the cell lines SW620, KMS-11,
and MDA-MB-175-VII. In an additional processing step, CpG sites were
compressed to CpG island with the deﬁnition from UCSC genome browser52,
resulting in a total of 26,313 CpG island based on either M or beta values.
Drug properties. The identity of all drugs was anonymized, but for all agents the
putative targets are revealed. The gene names of the protein targets are listed with
‘*’’ denoting any character if the target is a protein family. Furthermore, for 58
drugs the Molecular weight, H-bond acceptors, H-bond donors, calculated octanol-
water partition coefﬁcient, Lipinski’s rule of 5, and their SMILES (Simpliﬁed
Molecular Input Line Entry Speciﬁcation) are provided. Drugs were grouped into
pathways and biological processes manually according to their protein targets
(Supplementary Data 1).
Challenge organization. The Challenge consisted of two sub-challenges, each with
multiple rounds: a leaderboard, validation, bonus, and collaborative round. SC1
had four leaderboard rounds that lasted 8, 6, 5, and 5 weeks, while SC2 had three
leaderboard rounds that lasted 12, 7, and 5 weeks. Participants were given a lea-
derboard dataset to build a model and generate three prediction ﬁles per leader-
board round. Scores were returned to participants so that they can improve their
model throughout these rounds for their one submission to the ﬁnal round, which
was scored against a held-out dataset. The ﬁnal round lasted for 2 weeks, which was
then followed by a 9 week bonus round and 10 week collaborative round.
Challenge pharmacology data splits. In SC1, participants were asked to
predict drug synergy of 167 combinations in the panel of 85 cell lines. The synergy
data of each drug combination was partitioned into three sets: a training dataset
(3/6–50%), a leaderboard set (1/6–16.7%), and validation set (2/6–33%) of treated
cell lines. SC2 leveraged data for remaining 740 drug combinations not overlapping
with those used in SC1, although data for some of the same drugs (in combination
with different drugs), homologous drugs (i.e., same target, but different chemical
structure), and cell lines were included. A leaderboard set (370 combinations) and a
ﬁnal validation set (370 combinations) were randomly split, which are mutually
exclusive from each other, as well as from SC1.
Primary scoring metric of Sub-Challenge 1. With synergy scores roughly nor-
mally distributed and and outliers truncated to −100 and 100 (Supplementary
Fig. 2), Pearson’s correlation was employed as the base measure of prediction
accuracy within each drug combination. The primary metric was then the average
weighted Pearson correlation (ρw) of the predicted vs. observed synergy scores
across each individual drug combination, i. The weight for a given drug combi-
nation i was
ffiffiffiffiffiffiffiffiffiffiffiffi
ni  1
p
where ni is the number of cell lines treated with the drug
combination. This resulted in the following primary metric for SC1A&B,
ρw ¼
PN
i¼1
ffiffiffiffiffiffiffiffiffiffiffiffi
ni  1
p
ρiPN
i¼1
ffiffiffiffiffiffiffiffiffiffiffiffi
ni  1
p ; ð1Þ
where N`= 167 were the tested drug combinations.
Tie-breaking scoring metric of Sub-Challenge 1. The tie-breaking metric was
identical to the primary metric Eq. 1 except that it was applied to the subset of
drug combinations that have at least one cell line with synergy score Sci  20in the
held-out test set (Sci= synergy score at cell line c and drug combination i). Neither
the subset of drug combinations nor its size (N= 118) was revealed to participants
prior to ﬁnal evaluation.
Primary scoring metric of Sub-Challenge 2. The primary metric was a sequential
three-way ANOVA, which tested the separation of held-out synergy scores by
predicted synergy (=1) and predicted non-synergy (=0). In the sequential three-
way ANOVA (type 1), we controlled for systematic drug and cell line effects, and
evaluated variance explained by a given team’s synergy predictions. We deﬁne
the primary metric as
SA ¼ sgn ´ log10ðpÞ; ð2Þ
where sgn is the sign of the effect size (positive or negative separation by
prediction), and p is the P-value (F-statistic) computed from the ANOVA
distinguishing predicted synergy (=1) from predicted non-synergy (=0) across all
experimentally measured synergy scores.
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This three-way ANOVA score can be interpreted via linear regression where
the intercept is set to 0.
y  β1  dcþ β2  clþ β3  x ð3Þ
Here, the response variable y is the observed synergy, which is normally
distributed, and there are three predictive features: dc= drug combination, cl= cell
line and a teams binary synergy predictions x. Then the primary metric,
SA ¼ log10ðp:value½β3Þxsignðβ3Þ, measures the signiﬁcance of a team’s
predictions after controlling for variance associated with cell line and and drug
combinations.
Tie-breaking scoring metric of Sub-Challenge 2. As the tie-breaking metric, we
used balanced accuracy (BAC) using discretized synergy scores Sci  20to evaluate
the binary classiﬁers submitted in this sub-challenge. This metric evaluates both the
sensitivity and speciﬁcity of the classiﬁers while taking into account the low pro-
portion of synergistic cases to un-synergistic.
Application of the Tie-Breaking Metric. In each sub-challenge, we estimated a
Bayes Factor (BF) using a paired bootstrapped approach to determine whether
a team’s score was statistically indistinguishable from another. In the event that a
team’s scores were determined to be statistically equivalent, we then applied the tie-
breaking metric. To estimate the BF, we sample with replacement from the M
observations of the given sub-challenge and computing the primary metric (pm)
for each team 1000 times. For a given team, T, KT was computed by
KT ¼
P1000
i¼1 pmT;i<pmbest;i
P1000
i¼1 pmT;i  pmbest;i
ð4Þ
Where pmbest;iis the bootstrapped primary metric at iteration i for the team with
the highest primary metric (non-bootstrapped).
Assessing performance of individual combinations. Combinations deﬁned as
poorly predicted had an average predicted vs. observed Pearson correlation across
teams in the range seen with a random predictor (SC1 Primary metric=−0.25 and
0.25). In contrast, well predicted combinations had an average Pearson correlation
across teams of above 0.5.
Independent validation on O’Neil et al. Merck screen. In order to assess the
utility of features and the predictability of the learning algorithms in new contexts,
we provided the participants an independent large-scale oncology combination
screen published recently4. The O'Neil et al.4 dataset consists of 22,737 experi-
mental endpoints covering 583 doublet combinations across 39 diverse cancer cell
lines. Thirty-eight experimental drugs and approved drugs were included in this
combination screen using a 4-by-4 dosing regimen. Raw cell viability measures for
each combination experiment were processed through Combeneﬁt11 to generate
synergy scores as per the Challenge dataset. While there are 6 approved drugs,
49 targets, and 10 cell lines in common between the Challenge and O'Neil et al.4
datasets, the total number of exact experiments (Drug A–Drug B–Cell line)
overlapping is below 100, giving the participants a highly independent validation
set for their prediction algorithms. This information was provided to best per-
forming teams in the Challenge, along with a dictionary of curated chemical
structures and putative targets for each. Prediction models were trained on the
released Challenge dataset and made synergy score predictions on the O'Neil et al.
dataset. Metrics for SC1 and SC2 were used to assess prediction performance.
Individual prediction models. Full description and implementation of models
used by teams in the ﬁnal submission to DREAM can be downloaded from:
Synapse.org/
AstraZeneca_Sanger_Drug_Combination_Challenge_Leaderboards [http://www.
synapse.org/AstraZeneca_Sanger_Drug_Combination_Challenge_Leaderboards].
Top-performing prediction models in SC1 and SC2 made use of genetic features
relating to the gene targets of the drugs. Feature selection from the models enabled
nomination of putative biomarkers for drug combination synergy (Supplementary
Methods).
Ensemble models. SC2 participant models were aggregated using two types of
ensemble models Spectral Meta-Learner (SML) and Random Aggregation. SML
choses predictions from n methods to aggregate based on an estimation of BAC for
each method without using actual labels15,53. Random Aggregation is the tradi-
tional way that people aggregate models by giving equal weight to each method.
We randomly pick n methods (do this ten times) and for n methods we compute
the average BAC and the error.
Monotherapy biomarkers and synergy enrichment. Monotherapy markers
are the mutational status of genes, either mutated or copy number altered, from
the pan-cancer binary event matrix (BEM)12, which separate the monotherapy
response into sensitive vs. non-response. The likelihood of separation was
estimated with a Wilcoxon Rank Sum test (Supplementary Methods). From most
signiﬁcant monotherapy marker to lowest in 0.1 steps of –log10(P-value), we
accumulative evaluated the percentage of synergistic combinations (synergy score
≥20) with at least one monotherapy marker. This analysis was bootstrapped ﬁve
times with 80% of the pharmacology data (Supplementary Methods).
Synergy biomarkers. A short list of putative synergy biomarkers were derived
from the ﬁve highest ranked features of well predicted drug combinations (Pearson
r > 0.5) from the two best performers NAD and DMIS. Features were ranked based
on their feature weight or importance for given well predicting model. This gene-
to-combination short list, was ﬁltered for associations predicted by both teams, or
genes biological related to the drug target deﬁned as either the gene being the target
itself, a short distance to it in OmniPath signaling network (two molecules up- or
downstream) or GO term similarity54 larger than 0.7. This resulted in a list of 47
gene-to-combination associations that we further studied. A gene within this list is
considered mutant if it was deleted, ampliﬁed (>7 copies) or mutated in any sense,
resulting in an extended BEM12. We calculated the P-value for each suggested
association with an ANOVA correcting for tissue of origin and multiple hypothesis
testing via Benjamini Hochberg. The effect sizes is the mean difference in synergy
score between mutant and wild-type cell lines.
For external validation of those putative biomarkers of synergy, we focused on
drug combinations in O’Neil et al.4, ALMANAC13, and additional experimental
data from AstraZeneca (Supplementary Data 3). We validated biomarkers in two
different contexts, (i) for cell lines overlapping with AZ-DREAM, considered as
biological replicates, and (ii) cells non-overlapping for predictions on independent
cell lines.
Literature evidence for the shortlisted combination-biomarker associations
was identiﬁed through PubMed search. The aim was to identify published evidence
of (i) the combination-biomarker association, (ii) the combination but not the
speciﬁc biomarker, and (iii) either one of the targets and the biomarker association.
The publications were further categorized into in vitro, in vivo, and preclinical
studies. Publications that discuss the speciﬁc combination-biomarker association
have been highlighted in red (Supplementary Data 3). In summary, synergy
biomarker were derived from best performer models, and highlighted based
external validation, as well as literature support.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data used for this study are available from the Genomics of Drug Sensitivity in
Cancer (GDSC [http://www.cancerrxgene.org/downloads/]) repository12, the Catalog of
Somatic Mutations in Cancer (COSMIC[http://cancer.sanger.ac.uk/cell_lines])
database55, the European Genome-phenome Archive (EGA) EGAS00001000978, Gene
Expression Omnibus (GEO) GSE68379, ArrayExpress E-MTAB-3610, Synapse database
synapse.org/DrugCombinationChallenge[https://www.synapse.org/
DrugCombinationChallenge] and the AstraZeneca Open Innovation Portal
openinnovation.astrazeneca.com/data-library.html[https://openinnovation.astrazeneca.
com/data-library.html].
Code availability
Full description and source code of all participants in this Challenge can be downloaded
from synapse.org/DrugCombinationChallenge[https://www.synapse.org/
DrugCombinationChallenge].
Received: 12 February 2018 Accepted: 1 April 2019
References
1. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G.
Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726
(2013).
2. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation.
Cell 144, 646–674 (2011).
3. Dry, J. R., Yang, M. & Saez-Rodriguez, J. Looking beyond the cancer cell
for effective drug combinations. Genome Med. 8, 125 (2016).
4. O’Neil, J. et al. An unbiased oncology drug screen to identify novel
combination strategies. Mol. Cancer Ther. 15, 1155–1162 (2016).
5. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for
cancer in the post-genomic era. Nat. Biotechnol. 30, 679–692 (2012).
6. Bulusu, K. C. et al. Modelling of drug combination effects and applications
to efﬁcacy and toxicity: state-of-the-art, challenges and perspectives.
Drug Discov. Today 21, 225–238 (2016).
7. Bansal, M. et al. A community computational challenge to predict the activity
of pairs of drugs. Nat. Biotechnol. 32, 1213–1222 (2014).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2
12 NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications
8. Gao, H. et al. High-throughput screening using patient-derived tumor
xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325
(2015).
9. Saez-Rodriguez, J. et al. Crowdsourcing biomedical research: leveraging
communities as innovation engines. Nat. Rev. Genet. 17, 470–486 (2016).
10. Loewe, S. Effect of combinations : mathematical basis of problem. Arch. Exp.
Pathol. Pharmakol. 114, 313–326 (1926).
11. Di Veroli, G. Y. et al. Combeneﬁt: an interactive platform for the analysis and
visualization of drug combinations. Bioinformatics 32, 2866–2868
(2016).
12. Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in. Cancer Cell
166, 740–754 (2016).
13. Holbeck, S. L. et al. The National Cancer Institute ALMANAC: A
comprehensive screening resource for the detection of anticancer drug
pairs with enhanced therapeutic activity. Cancer Res. 77, 3564–3576 (2017).
14. Marbach, D. et al. Wisdom of crowds for robust gene network inference.
Nat. Methods 9, 796–804 (2012).
15. Parisi, F., Strino, F., Nadler, B. & Kluger, Y. Ranking and combining multiple
predictors without labeled data. Proc. Natl Acad. Sci. USA 111, 1253–1258
(2014).
16. Gene Ontology Consortium. Gene Ontology Consortium: going forward.
Nucl. Acids Res. 43, D1049–D1056 (2015).
17. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as
a reference resource for gene and protein annotation. Nucl. Acids Res 44,
D457–D462 (2016).
18. Babur, Ö. et al. Systematic identiﬁcation of cancer driving signaling pathways
based on mutual exclusivity of genomic alterations. Genome Biol. 16, 45
(2015).
19. Türei, D., Korcsmaros, T. & Saez-Rodriguez, J. OmniPath: guidelines and
gateway for literature-curated signaling pathway resources. Nat. Methods 13,
966–967 (2016).
20. López-Otín, C. & Hunter, T. The regulatory crosstalk between kinases and
proteases in cancer. Nat. Rev. Cancer 10, 278–292 (2010).
21. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature
504, 389–393 (2013).
22. Dent, P., Curiel, D. T., Fisher, P. B. & Grant, S. Synergistic combinations
of signaling pathway inhibitors: mechanisms for improved cancer therapy.
Drug Resist. Updat. 12, 65–73 (2009).
23. Eduati, F. et al. Drug Resistance mechanisms in colorectal cancer dissected
with cell type–speciﬁc dynamic logic models. Cancer Res. 77, 3364–3375
(2017).
24. Kirouac, D. C. et al. Clinical responses to ERK inhibition in BRAF(V600E)-
mutant colorectal cancer predicted using a computational model. NPJ Syst.
Biol. Appl. 3, 14 (2017).
25. Klinger, B. et al. Network quantiﬁcation of EGFR signaling unveils potential
for targeted combination therapy. Mol. Syst. Biol. 9, 673 (2013).
26. Silverbush, D. et al. Cell-speciﬁc computational modeling of the PIM pathway
in acute myeloid leukemia. Cancer Res. 77, 827–838 (2017).
27. Flobak, Å. et al. Discovery of drug synergies in gastric cancer cells predicted by
logical modeling. PLoS Comput. Biol. 11, e1004426 (2015).
28. Fallahi-Sichani, M. et al. Adaptive resistance of melanoma cells to RAF
inhibition via reversible induction of a slowly dividing de-differentiated state.
Mol. Syst. Biol. 13, 905 (2017).
29. Margolin, A. A. et al. Reverse engineering cellular networks. Nat. Protoc. 1,
662–671 (2006).
30. Lefebvre, C. et al. A human B-cell interactome identiﬁes MYB and FOXM1 as
master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377
(2010).
31. Fakhry, C. T. et al. Interpreting transcriptional changes using causal graphs:
new methods and their practical utility on public networks. BMC Bioinforma.
17, 318 (2016).
32. Leiserson, M. D. M. et al. Pan-cancer network analysis identiﬁes combinations
of rare somatic mutations across pathways and protein complexes. Nat. Genet.
47, 106–114 (2015).
33. Alvarez, M. J., Chen, J. C. & Califano, A. DIGGIT: a Bioconductor package
to infer genetic variants driving cellular phenotypes. Bioinformatics 31,
4032–4034 (2015).
34. Yi, Y. W. et al. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity
of EGFR kinase inhibitors in triple-negative breast cancer cells. J. Cell.
Mol. Med. 17, 648–656 (2013).
35. Wei, F. et al. mTOR inhibition induces EGFR feedback activation in
association with its resistance to human pancreatic cancer. Int. J. Mol. Sci. 16,
3267–3282 (2015).
36. Shi, X. -B. et al. Functional analysis of 44 mutant androgen receptors from
human prostate cancer. Cancer Res. 62, 1496–1502 (2002).
37. Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M. & Triﬁro, M. The
androgen receptor gene mutations database: 2012 update. Hum. Mutat. 33,
887–894 (2012).
38. Eisermann, K., Wang, D., Jing, Y., Pascal, L. E. & Wang, Z. Androgen receptor
gene mutation, rearrangement, polymorphism. Transl. Androl. Urol. 2,
137–147 (2013).
39. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen
receptor signaling in PTEN-deﬁcient prostate cancer. Cancer Cell 19, 575–586
(2011).
40. Zhu, M. -L. & Kyprianou, N. Androgen receptor and growth factor
signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 15, 841–849
(2008).
41. Meng, X. et al. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-
PI3K-AKT activation. Int. J. Oncol. 49, 682–690 (2016).
42. Zheng, X. et al. ADAM17 promotes breast cancer cell malignant phenotype
through EGFR-PI3K-AKT activation. Cancer Biol. Ther. 8, 1045–1054 (2009).
43. Schwartz, S. et al. Feedback suppression of PI3Kα signaling in PTEN-mutated
tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 27, 109–122
(2015).
44. Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer beneﬁt
via patient-to-patient variability without drug additivity or synergy. Cell 171,
1678–1691 (2017). e13.
45. Lopez, J. S. & Banerji, U. Combine and conquer: challenges for targeted
therapy combinations in early phase trials. Nat. Rev. Clin. Oncol. 14, 57–66
(2016).
46. Di Veroli, G. Y. et al. An automated ﬁtting procedure and software for dose-
response curves with multiphasic features. Sci. Rep. 5, 14701 (2015).
47. Stephens, P. J. et al. The landscape of cancer genes and mutational processes
in breast cancer. Nature 486, 400–404 (2012).
48. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern
growth approach to detect break points of large deletions and medium sized
insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
49. Greenman, C. D. et al. PICNIC: an algorithm to predict absolute allelic copy
number variation with microarray cancer data. Biostatistics 11, 164–175
(2010).
50. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. Affy–analysis of
Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–315
(2004).
51. Du, P. et al. Comparison of Beta-value and M-value methods for
quantifying methylation levels by microarray analysis. BMC Bioinforma. 11,
587 (2010).
52. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12,
996–1006 (2002).
53. Jaffe, A., Nadler, B. & Kluger, Y. Estimating the accuracies of multiple
classiﬁers without labeled data. Artif. Intel. Stat. 38, 407–415 (2015).
54. Wappett, M. et al. Multi-omic measurement of mutually exclusive loss-of-
function enriches for candidate synthetic lethal gene pairs. BMC Genom. 17,
65 (2016).
55. Forbes, S. A. et al. COSMIC: exploring the world’s knowledge of somatic
mutations in human cancer. Nucl. Acids Res. 43, D805–D811 (2015).
Acknowledgements
We thank the Genomics of Drug Sensitivity in Cancer and COSMIC teams at the
Wellcome Trust Sanger Institute for help with the preparation of the molecular data,
Denes Turei for help with Omnipath, and Katjusa Koler for help with matching drug
names across combination screens. We thank AstraZeneca for funding and provision of
data to the DREAM Consortium to run the challenge, and funding from the European
Union Horizon 2020 research (under grant agreement No 668858 PrECISE to J.S.R.),
the Joint Research Center for Computational Biomedicine (which is partially funded by
Bayer AG) to J.S.R., National Institute for Health Research (NIHR) Shefﬁeld Biomedical
Research Center, Premium Postdoctoral Fellowship Program of the Hungarian Academy
of Sciences. M.G lab is supported by Wellcome Trust (102696 and 206194).
Author contributions
M.P.M., D.W., T.Y., I.S.J., T.No, G.Y.D., S.F., G.S., J.G., J.R.D., and J.S.R. designed the
challenge. The top-performing approach was designed by Y.G. Data analysis for the top-
performing approach was conducted by M.P.M,. D.W., M.M., B.S., K.C.B., J.K., M.J.,
R.W., T.Ng, and M.Z. The DREAM Consortium provided drug synergy and biomarker
predictions, as well as method implementations and descriptions. M.P.M., D.W., M.M.,
T.Y., E.C.N., R.V., and M.E.A. performed analysis of challenge predictions. M.P.M.,
D.W., M.M., B.S., and K.C.B. interpreted the results of the challenge and performed
follow-up analyses for the manuscript. E.K.Y.T., M.J.G., Z.G., and S.F. generated
experimental data. M.P.M., D.W., Y.G., M.M., B.S., K.C.B., T.Y., J.K., M.J., R.W., T.Ng,
M.Z., I.S.J., J.G., J.R.D., and J.S.R. wrote the manuscript. J.G., J.R.D., and J.S.R. supervised
the project.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09799-2.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications 13
Competing interests: K.C.B., Z.G., G.Y.D., E.K.Y.T., S.F., and J.R.D. are AstraZeneca
employees. K.C.B., Z.G., E.K.Y.T., S.F., and J.R.D. are AstraZeneca shareholders. Y.G.
receives personal compensation from Eli Lilly and Company, is a shareholder of Cleerly, Inc.,
and Ann Arbor Algorithms, Inc. M.G. receives research funding from AstraZeneca and has
performed consultancy for Sanoﬁ. The remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewers for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
AstraZeneca-Sanger Drug Combination DREAM Consortium
Jordi Abante18, Barbara Schmitz Abecassis19, Nanne Aben20,21, Delasa Aghamirzaie22, Tero Aittokallio23,
Farida S. Akhtari24, Bissan Al-lazikani25, Tanvir Alam26, Amin Allam27, Chad Allen28,
Mariana Pelicano de Almeida19, Doaa Altarawy29,30, Vinicius Alves31, Alicia Amadoz32, Benedict Anchang33,
Albert A. Antolin25, Jeremy R. Ash34, Victoria Romeo Aznar35, Wail Ba-alawi26, Moeen Bagheri36,
Vladimir Bajic26, Gordon Ball37, Pedro J. Ballester38,39,40,41, Delora Baptista42, Christopher Bare4,
Mathilde Bateson43, Andreas Bender28, Denis Bertrand44, Bhagya Wijayawardena45, Keith A. Boroevich46,
Evert Bosdriesz20,47, Salim Bougouffa26, Gergana Bounova20, Thomas Brouwer48, Barbara Bryant49,
Manuel Calaza50, Alberto Calderone51, Stefano Calza52,53, Stephen Capuzzi31, Jose Carbonell-Caballero54,
Daniel Carlin55, Hannah Carter55, Luisa Castagnoli56, Remzi Celebi57, Gianni Cesareni56, Hyeokyoon Chang9,
Guocai Chen58, Haoran Chen59, Huiyuan Chen60, Lijun Cheng45, Ariel Chernomoretz35, Davide Chicco61,
Kwang-Hyun Cho62, Sunghwan Cho62, Daeseon Choi63, Jaejoon Choi64, Kwanghun Choi9, Minsoo Choi63,
Martine De Cock65, Elizabeth Coker25, Isidro Cortes-Ciriano66, Miklós Cserzö5,6, Cankut Cubuk67,
Christina Curtis68, Dries Van Daele69, Cuong C. Dang38,39,40,41, Tjeerd Dijkstra70, Joaquin Dopazo67,
Sorin Draghici71,72, Anastasios Drosou73, Michel Dumontier74, Friederike Ehrhart19, Fatma-Elzahraa Eid29,75,
Mahmoud ElHefnawi76,77, Haitham Elmarakeby29,75, Bo van Engelen19, Hatice Billur Engin55, Iwan de Esch78,
Chris Evelo19, Andre O. Falcao79, Sherif Farag31, Carlos Fernandez-Lozano80, Kathleen Fisch81,
Asmund Flobak82,83, Chiara Fornari1, Amir B.K. Foroushani84, Donatien Chedom Fotso85, Denis Fourches86,
Stephen Friend4, Arnoldo Frigessi87, Feng Gao88, Xiaoting Gao89, Jeffrey M. Gerold90, Pierre Gestraud91,
Samik Ghosh92, Jussi Gillberg93, Antonia Godoy-Lorite94, Lizzy Godynyuk19, Adam Godzik95,
Anna Goldenberg96, David Gomez-Cabrero37,97, Mehmet Gonen98,99, Chris de Graaf78, Harry Gray100,
Maxim Grechkin101, Roger Guimera94,102, Emre Guney103, Benjamin Haibe-Kains104, Younghyun Han62,
Takeshi Hase92, Di He105, Liye He23, Lenwood S. Heath29, Kristoffer H. Hellton106, Manuela Helmer-Citterich56,
Marta R. Hidalgo67, Daniel Hidru36, Steven M. Hill100, Sepp Hochreiter107, Seungpyo Hong108, Eivind Hovig109,110,
Ya-Chih Hsueh36, Zhiyuan Hu111, Justin K Huang112, R. Stephanie Huang113, László Hunyady5,6, Jinseub Hwang114,
Tae Hyun Hwang115, Woochang Hwang64, Yongdeuk Hwang116, Olexandr Isayev31, Oliver Bear Don’t Walk IV117,
John Jack24, Samad Jahandideh95, Jiadong Ji118,119,120, Yousang Jo62, Piotr J. Kamola46, Georgi K. Kanev78,
Loukia Karacosta33, Mostafa Karimi18, Samuel Kaski93, Marat Kazanov121,122, Abdullah M Khamis26,
Suleiman Ali Khan23, Narsis A. Kiani123, Allen Kim101, Jinhan Kim124, Juntae Kim62, Kiseong Kim62, Kyung Kim125,
Sunkyu Kim9, Yongsoo Kim20,126, Yunseong Kim62, Paul D.W. Kirk100, Hiroaki Kitano92, Gunter Klambauer107,
David Knowles33,127, Melissa Ko128, Alvaro Kohn-Luque129, Albert J. Kooistra78, Melaine A. Kuenemann86,
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2
14 NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications
Martin Kuiper82, Christoph Kurz130, Mijin Kwon62, Twan van Laarhoven131, Astrid Laegreid82, Simone Lederer131,
Heewon Lee9, Jeon Lee115, Yun Woo Lee63, Eemeli Lepp_aho93, Richard Lewis28, Jing Li60, Lang Li132,
James Liley133, Weng Khong Lim134,135, Chieh Lin136, Yiyi Liu89, Yosvany Lopez46,137,138, Joshua Low19,
Artem Lysenko46, Daniel Machado42, Neel Madhukar139, Dries De Maeyer140, Ana Belen Malpartida19,
Hiroshi Mamitsuka141, Francesco Marabita37, Kathleen Marchal140, Pekka Marttinen142, Daniel Mason28,
Alireza Mazaheri123, Arfa Mehmood143, Ali Mehreen144, Magali Michaut20, Ryan A. Miller19,
Costas Mitsopoulos25, Dezso Modos28, Marijke Van Moerbeke145, Keagan Moo101, Alison Motsinger-Reif24,
Rajiv Movva127, Sebastian Muraru19, Eugene Muratov31, Mushthofa Mushthofa146, Niranjan Nagarajan44,
Sigve Nakken147, Aritro Nath113, Pierre Neuvial147, Richard Newton148, Zheng Ning53, Carlos De Niz149,
Baldo Oliva150, Catharina Olsen145,151, Antonio Palmeri56, Bhawan Panesar36, Stavros Papadopoulos73,
Jaesub Park62, Seonyeong Park63, Sungjoon Park9, Yudi Pawitan53, Daniele Peluso56, Sriram Pendyala152,
Jian Peng153, Livia Perfetto56, Stefano Pirro56, Sylvia Plevritis33, Regina Politi31, Hoifung Poon154, Eduard Porta95,
Isak Prellner155, Kristina Preuer107, Miguel Angel Pujana156,157, Ricardo Ramnarine36, John E. Reid100,
Fabien Reyal158, Sylvia Richardson100, Camir Ricketts139, Linda Rieswijk19,159, Miguel Rocha42,
Carmen Rodriguez-Gonzalvez25, Kyle Roell24, Daniel Rotroff24, Julian R. de Ruiter20,160, Ploy Rukawa148,
Benjamin Sadacca158, Zhaleh Saﬁkhani104, Fita Saﬁtri161, Marta Sales-Pardo94, Sebastian Sauer162,
Moritz Schlichting19, Jose A. Seoane68, Jordi Serra156,157, Ming-Mei Shang37, Alok Sharma46,163,164,
Hari Sharma36, Yang Shen18, Motoki Shiga165, Moonshik Shin62, Ziv Shkedy166, Kevin Shopsowitz167, Sam Sinai90,
Dylan Skola112, Petr Smirnov104, Izel Fourie Soerensen168, Peter Soerensen168, Je-Hoon Song62, Sang Ok Song124,
Othman Soufan20, Andreas Spitzmueller169, Boris Steipe36, Chayaporn Suphavilai44,170, Sergio Pulido Tamayo69,
David Tamborero171, Jing Tang23, Zia-ur-Rehman Tanoli23, Marc Tarres-Deulofeu94, Jesper Tegner37,172,
Liv Thommesen82, Seyed Ali Madani Tonekaboni104, Hong Tran29, Ewoud De Troyer166, Amy Truong4,
Tatsuhiko Tsunoda46,137,138, Gábor Turu5,6, Guang-Yo Tzeng36, Lieven Verbeke140, Santiago Videla35,
Daniel Vis20, Andrey Voronkov147, Konstantinos Votis73, Ashley Wang36, Hong-Qiang Horace Wang173,
Po-Wei Wang136, Sheng Wang153, Wei Wang88, Xiaochen Wang89, Xin Wang88, Krister Wennerberg23,
Lorenz Wernisch100, Lodewyk Wessels20,21,47, Gerard J.P. van Westen174, Bart A. Westerman175,
Simon Richard White100, Egon Willighagen19, Tom Wurdinger175, Lei Xie176, Shuilian Xie18, Hua Xu58,
Bhagwan Yadav177, Christopher Yau178, Huwate Yeerna179, Jia Wei Yin37, Michael Yu112, MinHwan Yu9,
So Jeong Yun124, Alexey Zakharov180, Alexandros Zamichos73, Massimiliano Zanin181, Li Zeng89,
Hector Zenil123,182, Frederick Zhang36, Pengyue Zhang183, Wei Zhang55, Hongyu Zhao89, Lan Zhao184,
Wenjin Zheng58, Azedine Zouﬁr28 & Manuela Zucknick129
18Department of Electrical and Computer Engineering, Texas A&M University, College Station 77843, USA. 19Department of Bioinformatics -
BiGCaT NUTRIM Maastricht University, Maastricht 6229 ER, The Netherlands. 20Division of Molecular Carcinogenesis NKI, Amsterdam 1066 CX,
The Netherlands. 21Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, The Netherlands. 22Genetics Bioinformatics and
Computational Biology Virginia Tech, Blacksburg, VA 24061, USA. 23Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki
FI-00014, Finland. 24Bioinformatics Research Center North Carolina State University, Raleigh, NC 27695-7566, USA. 25The Institute of Cancer
Research, London SW3 6JB, UK. 26Computational Bioscience Research Center (CBRC) KAUST, Thuwal 23955, Saudi Arabia. 27King Abdullah
University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia. 28Centre for Molecular Informatics, Department of Chemistry,
University of Cambridge, Cambridge CB2 1EW, UK. 29Department of Computer Science Virginia Tech, Blacksburg, VA 24061, USA. 30Alexandria
University, Alexandria 21500, Egypt. 31Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill 27599, USA.
32Department of Bioinformatics, Igenomix SL, Valencia 46980, Spain. 33Department of Radiology, Stanford University, Drive, Stanford 94305, USA.
34Bioinformatics Research Center, Department of Chemistry, Department of Statistics, North Carolina State University, Raleigh, NC 27695, USA.
35Leloir Institute, Buenos Aires C1405 BWE, Argentina. 36University of Toronto, Toronto, ON M5S, Canada. 37Unit of Computational Medicine,
Department of Medicine, Solna SciLifeLab Center for Molecular Medicine Karolinska Institute, Solna SE-171 76, Sweden. 38INSERM U1068,
Marseille 13005, France. 39Institut Paoli-Calmettes, Marseille 13009, France. 40Aix-Marseille University, 13007 Marseille, France. 41CNRS
UMR7258, Marseille 13273, France. 42Centre Biological Engineering (CEB), University of Minho, Braga 4710-057, Portugal. 43Institut HyperCube,
Paris 92907, France. 44Computational and Systems Biology, Genome Institute of Singapore, Singapore 138672, Singapore. 45Indiana University
School of Medicine, Indianapolis 46202, USA. 46Center for Integrative Medical Sciences RIKEN Japan, Kobe, Hyogo 650-0047, Japan. 47Cancer
Genomics Netherlands, Utrecht 3584 CG, Netherlands. 48Computer Laboratory, University of Cambridge, Cambridge CB3 0FD, UK. 49Constellation
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications 15
Pharmaceuticals, Cambridge 2142, USA. 50CIMUS University of Santiago de Compostela, La Coruña 15001, Spain. 51Bioinformatics and
Computational Biology Unit, Department of Biology, University of Rome Tor Vergata, Rome 00133, Italy. 52Department of Molecular and
Translational Medicine, University of Brescia, Brescia 25123, Italy. 53Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
Stockholm SE-171 76, Sweden. 54Centre de Regulacio Genomica (CRG), Barcelona Institute for Science and Technology, Barcelona 08036, Spain.
55Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. 56Department of Biology, University of Rome Tor Vergata,
Rome 00133, Italy. 57Department of Computer Engineering, Ege University Turkey, Metro İstasyonu 35100, Turkey. 58University of Texas Health
Science Center, Houston 77030, USA. 59Texas A&M University, Station, College Station, TX 77843, USA. 60Case Western University, Cleveland
44106, USA. 61Princess Margaret Cancer Centre, Toronto M5G 2C1, Canada. 62Department of Bio and Brain Engineering, Korea Advanced Institute
of Science and Technology (KAIST), Daejeon 34141, South Korea. 63Department of Medical Information, Kongju Nationtional University, Gongju
32588, South Korea. 64Bio-Synergy Research Center, Daejeon 02451, Republic of Korea. 65University of Washington Tacoma, Tacoma 98402,
USA. 66Departement de Biologie Structurale et Chimie Institut Pasteur Unite de Bioinformatique Structurale CNRS UMR, 3825 Paris, France.
67Clinical Bioinformatic Area Fundacion Progreso y Salud CDCA Hospital Virgen del Rocio, Sevilla 41092, Spain. 68Stanford University, Stanford
94305, USA. 69KU Leuven, Leuven 3000, Belgium. 70Max Planck Institute for Developmental Biology, Tuebingen 72076, Germany. 71Department
of Computer Science, Wayne State University Michigan, Detroit 48202, USA. 72Department of Obstetrics and Gynecology, Wayne State University
Michigan, Detroit 48202, USA. 73CERTH-ITI, Thessaloniki GR 5700, Greece. 74Institute of Data Science, Maastricht University, Maastricht 6229
ER, Netherlands. 75Al-Azhar University, Cairo 11651, Egypt. 76National Research Centre, Cairo 12622, Egypt. 77Nile University, Cairo 12622, Egypt.
78Division of Medicinal Chemistry, AIMMS Vrije Universiteit, Amsterdam 1081 HZ, The Netherlands. 79LaSIGE Faculdade de Ciencias Universidade
de Lisboa Portugal, Lisboa 1749-016, Portugal. 80University of A Coruna, Coruña 15001, Spain. 81Center for Computational Biology and
Bioinformatics, University of California, San Diego, La Jolla, CA 92093, USA. 82Norwegian University of Science and Technology, Trondheim 7491,
Norway. 83St. Olav’s University Hospital, Trondheim 7030, Norway. 84Texas State University, San Marcos Texas, San Marcos 78666, USA.
85University of Oxford, Oxford OX1 2JD, UK. 86Bioinformatics Research Center, Department of Chemistry, North Carolina State University, Raleigh,
NC 27695, USA. 87Oslo Centre for Biostatistics and Epidemiology, University of Oslo and Oslo University Hospital Norway, Oslo 0317, Norway.
88Department of Biomedical Sciences, City University of Hong Kong, Hong Kong 999077, Hong Kong. 89Yale University, New Haven 06520, USA.
90Program for Evolutionary Dynamics, Harvard University, Cambridge 02138, USA. 91Institut Curie Inserm U900, Paris 75248, France. 92The
Systems Biology Institute Tokyo, Tokyo 141-0022, Japan. 93Department of Computer Science Aalto University, Espoo 02150, Finland.
94Departament d’Enginyeria, Quimica Universitat Rovira i Virgili, Tarragona 43007, Spain. 95Sanford Burnham Prebys Medical Discovery Institute,
Jolla 92037, USA. 96Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. 97Mucosal and Salivary Biology Division King’s College London
Dental Institute, London SE1 9RT, UK. 98College of Engineering, Koc University, Istanbul 34450, Turkey. 99School of Medicine, Koc University,
Istanbul 34450, Turkey. 100MRC Biostatistics Unit University of Cambridge, Cambridge CB2 0SR, UK. 101University of Washington, Seattle, WA
98195, USA. 102ICREA, Barcelona 08010, Spain. 103Joint IRB-BSC-CRG Program in Computational Biology Institute for Research in Biomedicine,
Barcelona 08028, Spain. 104Princess Margaret Cancer Centre, University Health Network, Toronto, M5G 2C1 ON, Canada. 105Ph.D. Program in
Computer Science, The Graduate Center, The City University of New York, New York 10016, USA. 106Department of Mathematics University of
Oslo, Oslo 0371, Norway. 107Institute of Machine Learning Johannes Kepler University Linz, Linz 4040, Austria. 108University of Wisconsin,
Madison 53706, USA. 109Department of Tumor Biology Institute for Cancer Research, Oslo University Hospital Norway, Oslo 0424, Norway.
110Department of Informatics University of Oslo, Oslo 0316, Norway. 111Wellcome Trust Centre for Human Genetics University of Oxford, Oxford
OX3 7BN, UK. 112Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA 92093, USA. 113University of
Minnesota, Minneapolis 55455, USA. 114Department of Computer Science and Statistics, Daegu University, Daegu 38453, South Korea.
115Department Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 116Department of Computer Science, The
University of Suwon, Suwon 16499, Republic of Korea. 117Department of Biomedical Informatics, Columbia University in the City of New York, New
York 10032, USA. 118School of Statistics Shandong, University of Finance and Economics, Jinan 250000, China. 119Department of Computer
Science, Hunter College, The City University of New York, New York, NY 10065, USA. 120Department of Biostatistics, School of Public Health
Shandong University China, Shandong 250012, China. 121Skolkovo Institute of Science and Technology, Moscow 121205, Russia. 122A.A.Kharkevich
Institute for Information Transmission Problems, Moscow 127051, Russia. 123Algorithmic Dynamics Lab Unit of Computational Medicine,
Department of Medicine Solna, SciLifeLab Center for Molecular Medicine Karolinska Institute, Solna SE-171 76, Sweden. 124Standigm Inc, Seoul
06250, Korea. 125Department of Bioengineering, University of Washington, Seattle 98195, USA. 126Division of Oncogenomics NKI, Amsterdam
1066 CX, The Netherlands. 127Department of Genetics, Stanford University, Stanford 94305, USA. 128Department of Cancer Biology, Stanford
University Stanford, Stanford 94305, USA. 129Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo
0317, Norway. 130Helmholtz Zentrum Munchen Institute of Health Economics and Health Care Management, Neuherberg 85764, Germany. 131Data
Science Radboud University, Nijmegen 6525, Netherlands. 132The Ohio State University College of Medicine, Department of Biomedical Informatics,
Columbus 43210, USA. 133Department of Medicine, University of Cambridge, Cambridge CB2 0SP, UK. 134Centre for Computational Biology Duke-
NUS, Medical School Singapore, Singapore 169857, Singapore. 135SingHealth Duke-NUS Institute of Precision Medicine Singapore, Singapore
169857, Singapore. 136Carnegie Mellon University, Pittsburgh 15213, USA. 137Department of Medical Science, Mathematics Medical Research
Institute Tokyo Medical and Dental University, Tokyo 113-8510, Japan. 138CREST JST, Tokyo 102-0076, Japan. 139Weill Cornell Medicine, New York,
NY 10065, USA. 140Ghent University, Gent 9000, Belgium. 141Bioinformatics Center Institute for Chemical Research Kyoto University, Kyoto 611-
0011, Japan. 142Helsinki Institute for Information Technology HIIT, Department of Computer Science, Aalto University Finland, Espoo 02150, Finland.
143University of Turku, Turku 20500, Finland. 144Helsinki University, Helsinki 00100, Finland. 145Interuniversity Institute of Bioinformatics in
Brussels, Ixelles 1050, Belgium. 146Ghent University Bogor Agricultural University, Gent 9000, Belgium. 147Institut de Mathematiques de Toulouse,
Universite Paul Sabatier, Toulouse 31400, France. 148University of Cambridge, Cambridge CB2 8PQ, UK. 149Texas Tech University, Lubbock 79409,
USA. 150Structural Bioinformatics Group GRIB IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra Barcelona, Catalonia
08041, Spain. 151Machine Learning Group (MLG), Department d’Informatique, Universite libre de Bruxelles (ULB), Brussels 1050, Belgium.
152Harvard University, Cambridge 02138, USA. 153University of Illinois at Urbana-Champaign Urbana, Champaign 61820, USA. 154Microsoft
Research Redmond, Redmond 98052, USA. 155Cambridge Rindge and Latin High School, Cambridge 02138, USA. 156Catalan Institute of Oncology
(ICO), Barcelona 199 08908, Spain. 157Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona 199 08908, Spain. 158Institut Curie
RT2 Lab, Paris 75248, France. 159Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720,
USA. 160Division of Molecular Pathology NKI, Amsterdam 1066 CX, The Netherlands. 161Kyungpook National University, Daegu 41566, South Korea.
162FOM University of Applied Sciences, Essen 45127, Germany. 163Institute for Integrated and Intelligent Systems Grifﬁth University, Mount Gravatt,
QLD 4111, Australia. 164University of the South Paciﬁc Fiji, Suva, Fiji. 165Department of Electrical Electronic and Computer Engineering, Gifu
University, Gifu 501-1193, Japan. 166Center for Statistics, Hasselt University Belgium, Hasselt 3590, Belgium. 167Faculty of Medicine, University of
British Columbia, Kelowna V1Y 1T3, Canada. 168Center for Quantitative Genetics and Genomics, Department of Biology and Genetics, Aarhus
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2
16 NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications
University, Aarhus 8000, Denmark. 169Technische Universitat Munchen, München 80333, Germany. 170Department of Computer Science, National
University of Singapore, Singapore 117417, Singapore. 171Research Unit on Biomedical Informatics, University Pompeu Fabra UPF, Barcelona 08041,
Spain. 172Biological and Environmental Science and Engineering, Division KAUST, Thuwal 23955, Saudi Arabia. 173Cancer Hospital of Chinese
Academy of Sciences, Hefei 230031, China. 174Drug Discovery and Safety Leiden, Academic Centre for Drug Research, Leiden University,
Einsteinweg 55, Leiden 2333 CC, The Netherlands. 175Department of Neurosurgery, Cancer Center, Amsterdam 1012 WX, The Netherlands.
176Department of Computer Science, Hunter College and The Graduate Center, The City University of New York, New York, NY 10016, USA.
177Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki and Helsinki University Hospital
Comprehensive Cancer Center, Helsinki 00029, Finland. 178Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15
2SY, UK. 179University of California, San Diego, SD 92093, USA. 180National Center for Advancing Translational Sciences National Institutes of
Health, Rockville, MD 20892, USA. 181Universidad Politecnica de Madrid, Madrid 28040, Spain. 182Oxford Immune Algorithmics Ltd, Oxford RG1
3EU, UK. 183Indiana University - Purdue University, Indianapolis 47907, USA. 184Department of Electronic Engineering, City University of Hong
Kong, Hong Kong 999077, Hong Kong
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09799-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2674 | https://doi.org/10.1038/s41467-019-09799-2 | www.nature.com/naturecommunications 17
